09.11.19
Durvalumab combined with chemotherapy improves overall survival in patients with lung cancer: First-line treatment reduces mortality risk by 27%
Adding immunotherapy in the form of durvalumab to chemotherapy improves overall survival in patients with extensive-stage small cell lung cancer, according to research presented today at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (IASLC). The research was presented by Dr. Luis Paz-Ares, from